Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas
- PMID: 16103075
- DOI: 10.1158/0008-5472.CAN-04-4171
Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas
Abstract
It is widely accepted that angiogenesis is required for tumor progression. Vascular endothelial growth factor (VEGF) is a key molecule for tumor angiogenesis; however, its expressional regulation is not well understood during all stages of tumorigenesis. Using cell lines and surgical specimens of human non-small cell lung cancers (NSCLCs), we here show that platelet-derived growth factor-AA (PDGF-AA) is an essential autocrine regulator for VEGF expression. To directly assess the expression of PDGF-AA-dependent VEGF and its roles in tumorigenesis, we stably transfected established cell lines with their antisense genes. In addition, the levels of PDGF-AA and VEGF expression in surgical sections were measured and compared with clinicopathologic findings such as tumor size and patient prognosis. PDGF-AA tightly regulated VEGF expression and had a greater effect on tumor size and patient prognosis than did VEGF in both cell lines and surgical sections. PDGF-AA expression was not seen in the atypical adenomatous hyperplasia at all, whereas VEGF was occasionally seen. Furthermore, the frequency of VEGF expression was higher in advanced NSCLCs than in precancerous lesions, which was tightly correspondent to the results for PDGF-AA. These results indicate that PDGF-AA is an important regulator of the frequency and level of VEGF expression during the transition from a precancerous lesion to advanced cancer. The PDGF-AA/VEGF axis, therefore, may be a ubiquitous autocrine system for enhancing angiogenic signals, and PDGF-AA, and its related pathways could be a more efficient target of antiangiogenic therapy for cancers than VEGF and its pathways.
Similar articles
-
The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.Int J Oncol. 2009 Jan;34(1):255-61. Int J Oncol. 2009. PMID: 19082496
-
Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma.Cancer. 2002 Nov 15;95(10):2196-201. doi: 10.1002/cncr.10936. Cancer. 2002. PMID: 12412174
-
Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.Lung Cancer. 2009 Dec;66(3):314-8. doi: 10.1016/j.lungcan.2009.02.013. Epub 2009 Mar 25. Lung Cancer. 2009. PMID: 19324448
-
Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.Lung Cancer. 2006 Feb;51(2):143-58. doi: 10.1016/j.lungcan.2005.09.005. Epub 2005 Dec 19. Lung Cancer. 2006. PMID: 16360975 Review.
-
Prognostic role of angiogenesis in non-small cell lung cancer.Anticancer Res. 2001 Nov-Dec;21(6B):4373-82. Anticancer Res. 2001. PMID: 11908693 Review.
Cited by
-
PDGF/VEGF system activation and angiogenesis following initial post ovariectomy meningeal microvessel loss.Cell Cycle. 2008 May 15;7(10):1385-90. doi: 10.4161/cc.7.10.5819. Epub 2008 Feb 25. Cell Cycle. 2008. PMID: 18418080 Free PMC article.
-
An insight into the invasion of breast ductal carcinoma in situ based on clinical, pathological and hematological data.PeerJ. 2022 Aug 31;10:e13966. doi: 10.7717/peerj.13966. eCollection 2022. PeerJ. 2022. PMID: 36065403 Free PMC article.
-
Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.Invest New Drugs. 2013 Dec;31(6):1487-98. doi: 10.1007/s10637-013-0010-4. Epub 2013 Aug 22. Invest New Drugs. 2013. PMID: 23963796 Free PMC article. Clinical Trial.
-
Bevacizumab in the treatment of NSCLC: patient selection and perspectives.Lung Cancer (Auckl). 2017 Dec 14;8:259-269. doi: 10.2147/LCTT.S110306. eCollection 2017. Lung Cancer (Auckl). 2017. PMID: 29276417 Free PMC article. Review.
-
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer.Br J Cancer. 2009 Nov 3;101(9):1543-8. doi: 10.1038/sj.bjc.6605346. Epub 2009 Oct 13. Br J Cancer. 2009. PMID: 19826424 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical